Premium
Treatment of intracranial human glioblastoma by direct intratumoral administration of 131 I‐labelled anti‐tenascin monoclonal antibody BC‐2
Author(s) -
Riva P.,
Arista A.,
Sturiale C.,
Moscatelli G.,
Tison V.,
Mariani M.,
Seccamani E.,
Lazzari S.,
Fagioli L.,
Franceschi G.,
Sarti G.,
Riva N.,
Natali P. G.,
Zardi L.,
Scassellati G. A.
Publication year - 1992
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910510103
Subject(s) - radioimmunotherapy , tenascin , medicine , radiation therapy , monoclonal antibody , chemotherapy , nuclear medicine , glioma , pathology , tenascin c , antibody , immunohistochemistry , cancer research , chemistry , immunology , extracellular matrix , biochemistry , fibronectin
Ten patients with bulky brain glioblastoma, recurring after surgery, radiotherapy or chemotherapy, underwent direct intralesional radioimmunotherapy (RIT) using a monoclonal antibody (MAb), BC‐2, raised against tenascin and labelled with 131 I. Tenascin, the BC‐2‐recognized glycoprotein, is an antigen expressed by the stroma of malignant gliomas but not by normal cerebral tissue. Preliminary studies in animals have demonstrated the ability of anti‐tenascin radiolabelled MAbs to detect and reduce tumours. A mean MAb dose of 1.93 mg (corresponding to 551.3 MBq of 131 I) was injected directly into the tumour by means of a stereotaxic technique. Both systemic and local toxicity were negligible. After 24 hr, average tumour BC‐2 uptake was 4.9% per gram and its effective half‐life in neoplastic tissue was 66.5 hr: a mean radiation dose to target tissue of 36.48 cGy per MBq of injected 131 I was delivered. Normal brain tissue and the major organs were spared. Most patients underwent multiple injections, reaching a cumulative tumour radiation ranging from 7,000 to 41,000 cGy. RIT failed to achieve any result in 4 of the 10 patients; in 3, the disease was stabilized; in the remaining 3, CT scan or NMR revealed 2 partial remission (>50% reduction in tumour volume; PR) and I complete remission (CR). One patient with PR relapsed after 11 months; the other 2 patients were still maintaining their responses at the time of writing, 17 (CR) and 12 (PR) months after injection.